← SynDRA
LFM-A13
SynDRA canonical compound SYN1955772 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | BTK |
|---|
| Mechanism of action | Bruton's tyrosine kinase (BTK) inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- Bruton's tyrosine kinase (BTK) inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- FYN
- SLC6A3
- SLC6A2
- MAOA
- HTR2B
- HTR2C
- ABCB1
- HTR6
- MC3R
- MAPK3
- MAPK14
- MAPK1
- LCK
- KCNH2
- HTR2A
- MC5R
- HRH2
- HRH1
- HMGCR
- FLT1
- ESR2
- ESR1
- MC4R
- MMP9
- MMP1
- PTAFR
- TBXAS1
- TACR2
- TACR1
- SLC6A4
- SIGMAR1
- PTPRC
- PTGS2
- PTGS1
- PRKCA
- ACHE
- PPP3CA
- PDE5A
- OPRM1
- OPRK1
Cross-references
Synonyms
- (Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide
- SMR001230714
- SR-01000075965
- C11H8Br2N2O2
- 2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide
- BiomolKI_000050
- LFMA13
- BiomolKI2_000056
- AC1L1H0E
- AC1NS4I5
- Lopac0_000650
- SCHEMBL51142
- BSPBio_001239
- BMK1-F2
- MLS006010694
- MLS002153290
- GTPL9262
- CHEBI:95065
- 2-cyano-N-(2,5-dibromophenyl)
- MolPort-003-958-579
- HMS1362M21
- HMS3403M21
- HMS2235P16
- HMS1990M21
- HMS1792M21
- BCP12817
- 3781AH
- s7734
- BS0111
- ZINC37868487
- AKOS024456516
- CS-3890
Look up LFM-A13 in the interactive SynDRA portal →